α-干扰素加丝裂霉素C膀胱灌注防治浅表性膀胱癌复发的研究

Experience with intravesical instillation of recombinant interferon- alpha and mitomycin C therapy for superficial bladder tumors

目的 提高膀胱癌的治疗效果 ,降低膀胱癌术后复发率。 方法 42例膀胱癌患者术后分为两组 :(1)α 干扰素 +丝裂霉素C组 2 0例 ,α 干扰素 30 0 0万IU +丝裂霉素C 40mg +生理盐水 40ml膀胱灌注 ,(2 )丝裂霉素C组 2 2例 ,丝裂霉素C 40mg +生理盐水 40ml膀胱灌注。每周 1次 ,连续 6次 ,然后每 2周 1次 ,连续 6次 ,以后每月一次连续 2年。 结果 随访 6～ 30个月 (中位数 18个月 ) ,α 干扰素 +丝裂霉素C组复发 2例 ,复发率为 10 % ,丝裂霉素C组复发 8例 ,复发率为36 % ,两组比较差别有显著性意义 (卡方检验 ,P <0 .0 5 )。 结论 α 干扰素

Objective For preventing the recurrence of superficial transitional cell carcinoma of bladder. Methods Recombinant interferon-alpha and mitomycin C have been used combindly in cl inical study.42 patients were divided into two groups: recombinant interferon-a lpha plus mitomycin group and mitomycin C group.The protocol of chemoimmunoprop hylaxis include 6 weekly and 6 two weekly instillation of 3×10 7 IU recombinan t interferon-alpha plus 40mg mitomycin C in 40ml normal saline via catheter.Che moimmunotherapy was given once monthly for at least two years. Resul ts Follow-up(from 6 to 30 months with a median of 18 months)consist ed of cystoscopy and cytology with cold cup biopsies carried out every 3 months for 2 years. Recurrence after instillation of recombinant interferon-alpha plus mitomycin C was observed in only 2 (10%). Recombinant interferon-alpha plus mi tomycin C yielded better effect ive rate(P<0.05). Conclusions Recombinant interferon -alpha working in coordination with mitomycin C had been effective for preventi ng the recurrence of sperficial transitional cell carcinoma of bladder.The intra vesical recombinant interferon-alpha plus mitomycin C appears to be more effect ive against recurrence than mitomycin C alone.